EGFR and collecting duct carcinoma: A phase III trial evaluating erlotinib with gemcitabine and oxaliplatin in metastatic BDC was negative, with molecular subgroup analysis showing only two patients with EGFR mutations (T790M) treated with chemotherapy alone [53].